Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,662
  • Shares Outstanding, K 16,258
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,470 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings $-0.16 on 03/27/26
  • Next Earnings Date 05/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +322,358.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7600 +10.57%
on 03/30/26
1.2600 -33.31%
on 03/12/26
-0.1697 (-16.80%)
since 02/27/26
3-Month
0.7508 +11.92%
on 02/04/26
1.2600 -33.31%
on 03/12/26
-0.1697 (-16.80%)
since 12/26/25
52-Week
0.6600 +27.32%
on 04/08/25
2.1150 -60.27%
on 09/23/25
-0.1897 (-18.42%)
since 03/28/25

Most Recent Stories

More News
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Technology Selectively Shuts Down Cancer Reproducing Cells

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers

HOTH : 0.8403 (+9.12%)
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy®️...

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with...

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTCAE)...

HOTH : 0.8403 (+9.12%)
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets

HOTH : 0.8403 (+9.12%)

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.9297
2nd Resistance Point 0.8898
1st Resistance Point 0.8651
Last Price 0.8403
1st Support Level 0.8005
2nd Support Level 0.7606
3rd Support Level 0.7359

See More

52-Week High 2.1150
Fibonacci 61.8% 1.5592
Fibonacci 50% 1.3875
Fibonacci 38.2% 1.2158
Last Price 0.8403
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.